Ergomed plc is dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. Operating with a global footprint in over 65 countries, Ergomed enables our clients to access solutions even for their toughest clinical development and trial management challenges from early phase to complex late stage programmes.
The AIM-quoted firm is also involved in a study at the Papa Giovanni XXIII Hospital in Bergamo,
